LncRNA PVT1 promotes gemcitabine resistance of pancreatic cancer via activating Wnt/β-catenin and autophagy pathway through modulating the miR-619-5p/Pygo2 and miR-619-5p/ATG14 axes.
Zhou C, Yi C, Yi Y, Qin W, Yan Y, Dong X, Zhang X, Huang Y, Zhang R, Wei J, Ali DW, Michalak M, Chen XZ, Tang J. · 2020
Read LncRNA PVT1 promotes gemcitabine resistance of pancreatic cancer via activating Wnt/β-catenin and autophagy pathway through modulating the miR-619-5p/Pygo2 and miR-619-5p/ATG14 axes. by Zhou C, Yi C, Yi Y, Qin W, Yan Y, Dong X, Zhang X, Huang Y, Zhang R, Wei J, Ali DW, Michalak M, Chen XZ, Tang J. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7389684.txt.
Introduction
Zhou and co-authors unravel how a long noncoding RNA makes pancreatic cancer resist chemotherapy, in Molecular Cancer. Pancreatic cancer is among the most lethal cancers, and resistance to the drug gemcitabine is a major obstacle. The RNA, called PVT1, had already been tied to cancer growth and drug resistance, but its mechanism here was unclear.
Working in cells and mouse tumor grafts, the team showed PVT1 raises two partners by soaking up a small RNA, miR-619-5p. One partner, Pygo2, switches on the Wnt growth pathway; the other, ATG14, drives autophagy, the cell's self-recycling system. Both help tumors survive gemcitabine. The chain offers several points where a future drug might restore sensitivity.
Catalog record
| CREATOR | Zhou C, Yi C, Yi Y, Qin W, Yan Y, Dong X, Zhang X, Huang Y, Zhang R, Wei J, Ali DW, Michalak M, Chen XZ, Tang J. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 95 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
LncRNA PVT1 promotes gemcitabine resistance of pancreatic cancer via activating Wnt/β-catenin and autophagy pathway through modulating the miR-619-5p/Pygo2 and miR-619-5p/ATG14 axes By Cefan Zhou, Changhua Yi, Yongxiang Yi, Wenying Qin, Yanan Yan, Xueying Dong, Xuewen Zhang, Yuan Huang, Rui Zhang, Jie Wei, Declan William Ali, Marek Michalak Published in: Molecular Cancer DOI: 10.1186/s12943-020-01237-y ABSTRACT Abstract Background Pancreatic cancer is one of the most lethal malignancies and has an extremely poor diagnosis and prognosis. The development of resistance to gemcitabine is still a major challenge. The long noncoding RNA PVT1 was reported to be involved in carcinogenesis and chemoresistance; however, the mechanism by which PVT1 regulates the sensitivity of pancreatic cancer to gemcitabine remains poorly understood. Methods The viability of pancreatic cancer cells was assessed by MTT assay in vitro and xenograft tumor formation assay in vivo. The expression levels of PVT1 and miR-619-5p were detected by quantitative real-time polymerase chain reaction (qRT-PCR). Western blotting analysis and qRT-PCR were performed to assess the protein and mRNA levels of Pygo2 and ATG14, respectively. Autophagy was explored via autophagic flux detection under confocal microscopy and autophagic vacuole investigation under transmission electron microscopy (TEM). The functional role and mechanism of PVT1 were further investigated by gain- and loss-of-function assays in vitro. Results In the present study, we demonstrated that PVT1 was up-regulated in gemcitabine-resistant pancreatic cancer cell lines. Gain- and loss-of-function assays revealed that PVT1 impaired sensitivity to gemcitabine in vitro and in vivo. We further found that PVT1 up-regulated the expression of both Pygo2 and ATG14 and thus regulated Wnt/β-catenin signaling and autophagic activity to overcome gemcitabine resistance through sponging miR-619-5p. Moreover, we discovered three TCF/LEF binding elements (TBEs) in the promoter region of PVT1, and activation of Wnt/β-catenin signaling mediated by the up-regulation of Pygo2 increased PVT1 expression by direct binding to the TBE region. Furthermore, PVT1 was discovered to interact with ATG14, thus promoting assembly of the autophagy specific complex I (PtdIns3K-C1) and ATG14-dependent class III PtdIns3K activity. Conclusions These data indicate that PVT1 plays a critical role in the sensitivity of pancreatic cancer to gemcitabine and highlight its potential as a valuable target for pancreatic cancer therapy. Keywords: PVT1, Gemcitabine resistance, Autophagy, miR-619-5p, Wnt/β-catenin BACKGROUND Pancreatic cancer is one of the most lethal malignancies due to its frequently late diagnosis, aggressive tumor growth and high level of metastasis. The overall 5-year survival rate of patients with pancreatic cancer is less than 5% [1]. Due to the low resection rate and high recurrence rate of pancreatic cancer, chemotherapy plays an important role in the comprehensive treatment of pancreatic cancer. Gemcitabine (2′,2 ‘-difluoro deoxycytidine (dFdC)) is a first-line chemotherapy drug approved for the treatment of advanced pancreatic cancer, either alone or in combination with other chemotherapeutic agents [2]. Although in recent clinical trials combinations of gemcitabine with other drugs resulted in relative improvements in median survival time, unfortunately, gemcitabine failed to significantly improve the overall prognosis and survival rates of pancreatic cancer patients, which was mainly caused by natural and/or acquired resistance to gemcitabine [3]. Thus, the inherent resistance of pancreatic cancer to currently available chemotherapeutic agents presents a major challenge. Therefore, the identification of genetic determinants of sensitivity to chemotherapeutic agents is imperative for the development of effective treatments and biomarkers for pancreatic cancer. Long noncoding RNAs (lncRNAs) comprise a heterogeneous family of RNA molecules longer than 200 nucleotides with no or limited protein-coding potential. LncRNAs mainly play their roles through the following mechanisms: 1) LncRNAs competitively adsorb miRNA as competing endogenous RNAs (ceRNAs) through base complementarity, resulting in the loss or reduction of miRNA function and controlling the regulation of miRNAs on target genes. 2) LncRNAs activate or inhibit certain cell activities by binding some epigenetic-related proteins to modify specific protein translation after transcription. 3) LncRNAs inhibit gene transcription by directly binding chromosomal DNA or promote gene transcription by recruiting transcription factors. 4) Finally, lncRNAs function as precursors of miRNAs [4]. Recent findings have highlighted the interaction of lncRNAs with cancer and chemotherapeutic resistance. For example, the lncRNAs HOTAIR and LINC00346 were reported to drive castration resistance in prostate cancer and promote pancreatic cancer growth and gemcitabine resistance, respectively [5]. The lncRNA human plasmacytoma variant translocation1 (PVT1), which is located downstream of the human chromosome 8q24 and proto-oncogene C-Myc, is highly expressed in a variety of tumor tissues or cell lines [6]. High PVT1 expression in these tumors is indicative of poor prognosis. Various studies have revealed that PVT1 plays important roles in carcinogenesis and chemoresistance [7]. Additionally, functional inactivation of the PVT1 gene could enhance gemcitabine sensitivity, whereas ectopic expression of PVT1 reversed this effect in ASPC-1 human pancreatic cancer cells [8]. However, the functional roles and mechanisms of PVT1 in the sensitivity of pancreatic cancer to gemcitabine treatment remain poorly understood and thus need to be further clarified. Macroautophagy (hereafter referred to as autophagy) is an evolutionarily ancient and highly conserved catabolic process. It begins with the formation of double-membrane vesicles known as autophagosomes that engulf cellular proteins and organelles for delivery to the lysosome [9]. Autophagy requires the involvement of several autophagy-related (ATG) proteins in response to nutrient depletion and subsequent adenosine 5′-monophosphate (AMP)-activated protein kinase (AMPK) activation or mechanistic target of rapamycin kinase (mTOR) inhibition [10, 11]. Autophagy is one of the mechanisms by which solid tumors resist hypoxia, ischemia and other harsh environments [12]. Autophagy has been shown to promote the tolerance of tumor cells to radiotherapy and chemotherapy [13, 14]. Blockade of autophagy with chloroquine also significantly increased the sensitivity of pancreatic cancer cells to gemcitabine [15]. The Wnt/β-catenin signaling pathway plays an important role in regulating various cellular activities, such as self-renewal, cell proliferation, embryonic development, tissue homeostasis and cell death [16]. Intracellular signal transduction by the Wnt/β-catenin signaling pathway is triggered when Wnt ligand proteins bind receptors of the Frizzled and LRP families on the cell surface. Through several cytoplasmic relay components, the signal is transduced to β-catenin, which enters the nucleus and forms a complex with TCF to activate the transcription of Wnt target genes [16]. Several studies have revealed that the activity of the Wnt/β-catenin signaling pathway could be induced and elevated under the conditions of chemotherapy [17]. Furthermore, pharmacological or genetic inhibition of Wnt activity restored the chemosensitivity of cancer cells, even in mouse models [18]. In this study, we attempted to investigate the contributions and mechanisms of the lncRNA PVT1 to the sensitivity of pancreatic cancer to gemcitabine. We demonstrated that PVT1 specifically promotes pancreatic cancer cell resistance to gemcitabine via increased Wnt/β-catenin pathway signaling and autophagic activity. We also indicated that PVT1 modulates gemcitabine resistance by the miR-619-5p/Pygo2 and miR-619-5p/ATG14 axes in pancreatic cancer cells. Moreover, we found that PVT1 is up-regulated by Pygo2 through increased binding of the β-catenin/TCF4 complex to its promoter region. Furthermore, we also showed that PVT1 interacts with ATG14 in the cytoplasm and promotes assembly of the PtdIns3K-C1 complex and the activation of ATG14-dependent class III PtdIns3K activity. Collectively, our findings highlight the role of PVT1 in the regulation of chemoresistance in pancreatic cancer. METHODS Cell lines, reagents, and antibodies Human pancreatic cancer cell lines PANC-1 and ASPC-1 were purchased from the cell center of Institute of Biochemistry and Cell Biology, Chinese